Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalifrelimab and Balstilimab in Advanced Solid Tumors and Cervical Cancer
NCT03495882Phase 2Completed
- Sponsor
- Agenus Inc.
- Start
- Dec 2017
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of zalifrelimab and balstilimab in solid tumor and Cervical Cancer (CC) (3 arms), sponsored by Agenus Inc. Primary endpoints: Objective Response Rate at 2 years and Dose-limiting Toxicities at 21 days. Started Dec 2017; status: completed.
02
Drugs
zalifrelimabbalstilimab
03
Conditions
solid tumorCervical Cancer (CC)
Beyond the preview
Go deeper on NCT03495882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495882.